 |
 |
 |
 |
||||
 |
 |
 |
 |
 |
 |
|
|
|
|
 |
 |
 |
 |
 |
 |
|
|
• Avera Pharmaceuticals Completes Enrollment In Phase 2 Social Anxiety Disorder Study
September 25, 2006
• Avera Pharmaceuticals Names Dinu Sen CHief Executive Officer
September 14, 2006
• Avera Pharmaceuticals Completes Successful
Phase 2 Study of Gantacurium Chloride for Endotracheal Intubation
June 27, 2006
•
Avera Pharmaceuticals Names Joao Siffert, M.D. as Vice-President, Clinical
Research and Development
June 9, 2005
•
Avera Pharmaceuticals Raises $48 million in Series C Venture Financing; New
Board Members Named
August 3, 2004
•
Avera Pharmaceuticals Inc. Licenses from Novartis AG Late-Stage Compound for
the Treatment of Depression
November 10, 2003
•
Avera Pharmaceuticals Inc. Raises $8 Million in Series B Venture Financing
October 28, 2003
•
Avera Pharmaceuticals Inc. Licenses Compound
With Promise In Psychiatry And Neurology From Eli Lilly And Company
December 17, 2002
•
Avera Pharmaceuticals Completes $16 Million Series
A Financing; Names Jeffrey F. McKelvy as President and CEO
May 22, 2002
•
Avera Pharmaceuticals Acquires From GlaxoSmithKline
A Proprietary Series of Neuromuscular Blockers
May 22, 2002
Home
| Company Profile | Strategy
| Therapeutic Interests | Product
Pipeline | Business Development | Contact
Us
© 2002-2006 Avera Pharmaceuticals, Inc.